anavex.com - AVXL Net Assets per Single Share

Anavex Life Sciences (AVXL) - corporate logo

Anavex Life Sciences (AVXL) is developing an asset-light strategy, concentrating its scientific research in the United States while outsourcing the manufacturing of dementia drugs to third-party enterprises. This price chart, where the indicator is fixed at 1.21, links this approach to the complete delegation of clinical trials to external contractors. Despite physicians' belief in the therapy's success, the company's market image remains speculative due to sharp price volatility.

Anavex (AVXL) Equity per Share: for the period 07/04/2022 - 10/28/2026

anavex.com - analytical breakdowns and key metrics (AVXL)

- price and consensus price forecast:
Stock Quotes Anavex Corp|AVXL - Broker Consensus Forecast
- market capitalization data:
Market Value Anavex Life Sciences Corp.|AVXL - Total Company Value
- book capitalization data:
Net Assets per Single Share Anavex Life Sciences|AVXL - Accounting Capitalization|Market Capitalization to Book Value Ratio anavex.com|AVXL - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Anavex Life Sciences|AVXL - Long-Term Debt to Capital|Short-Term Debt to Equity Anavex Life Sciences Corp.|AVXL - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Anavex Life Sciences Corp.
Fundamental company valuation:Anavex Corp, AVXL
Manufactured products of Anavex Life Sciences Corp.

Anavex Life Sciences is developing innovative dementia therapies through strategic alliances with neurological centers. This metric determines the net asset value per share, reflecting the business's actual asset base. Analyzing the calculated book value per share allows for the tracking of capital preservation between quarterly reports. The upward trend confirms the capitalization of intellectual property and resources. This serves as an indicator of the company's fundamental stability during a period of costly clinical trials.

Competitors of Anavex Life Sciences (AVXL)

Biogen Corp (BIIB) - Accounting Value per Share|NBIX: Equity per Share|Regencell Bioscience (RGC) - Net Assets per Single Share|AXSM (axsome.com) - Net Assets per Single Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|PRAX (Praxis Precision Medicines) - Book Value per Share|Book Value per Share CBLL|Net Assets per Single Share Prothena Biosciences PRTA|Equity per Share alector.com (ALEC)|Book Value per Share ANNX (Annexon Inc.)|OMER - Book Value per Share|NGNE - Accounting Value per Share|ACIU - Net Assets per Single Share|Book Value per Share VYGR|Net Asset Value per Share Neumora|Accounting Value per Share Scilex Holding Co. (SCLX)|Equity per Share Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Accounting Value per Share|Accounting Value of a Share CGTX (Cognition Therapeutics Inc.)|Net Assets per Single Share Inhibikase Therapeutics, Inc. IKT|Net Assets per Single Share Cassava Sciences Inc SAVA|Book Value per Share ASRT (Assertio Therapeutics)|COYA - Net Assets per Share|Book Value per Share vistagen.com (VTGN)|Ovid Therapeutics (OVID) - Share Book Value|Book Value per Share ABOS (Acumen Pharmaceuticals, Inc.)|Net Asset Value per Share CervoMed, Inc. (CRVO)|Alterity Therapeutics (ATHE) - Accounting Value per Share|Accounting Value of a Share CLNN (clene.com)|Net Assets per Single Share PEPG|Net Assets per Share Jupiter Neurosciences, Inc. JUNS|RLMD: Book Value per Share|ANVS - Accounting Value per Share|gracetx.com - Book Value per Share|Firefly Neuro (AIFF) - Net Assets per Share|Book Value per Share KLTO (ANEW Medical)|Net Asset Value per Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Accounting Value per Share Helius Medical Technologies, Inc. HSDT|PASG (Passage Bio Corp) - Book Value per Share|NEUP: Net Asset Value per Share|Minerva Neurosciences, Inc. - Net Assets per Single Share|Athira Pharma Inc (ATHA) - Net Assets per Share|ADXN (Addex Therapeutics, Ltd.) - Book Value per Share|Book Value per Share Alzamend (ALZN)|Accounting Value per Share Cyclerion Therapeutics (CYCN)|Net Assets per Single Share protagenic.com PTIX|KTTA - Accounting Value per Share|Cortigent Inc - Equity per Share|ATXI - Net Assets per Single Share|BCLI: Net Assets per Single Share|Net Assets per Single Share Cara Therapeutics, Inc.|chromocell.com (CHRO) - Equity per Share|Book Value per Share ELYM (Eliem Therapeutics, Inc.)|Net Asset Value per Share Intra-Cellular (ITCI)|Accounting Value per Share LBPH|Book Value per Share MRNS (Marinus Pharma)|Net Assets per Single Share NKGen Biotech, Inc.|neurobopharma.com - Accounting Value of a Share|SAGE (Sage Therapeutics) - Net Assets per Single Share|SNPX - Net Asset Value per Share|TRVN: Book Value per Share|VIGL (Vigil Neuroscience, Inc.) - Book Value per Share|Net Assets per Single Share Anew Medical (WENA)|Equity per Share cerevel.com